View More Recent Stories
-
Relay Therapeutics (RLAY) Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
-
Relay Therapeutics (RLAY) PT Lowered to $20 at BofA Securities
-
Relay Therapeutics, Inc. (RLAY) Tops Q2 EPS by 4c
-
Relay Therapeutics (RLAY) PT Lowered to $18 at H.C. Wainwright

